Geenscren back when they partnered with Novogen in late 2013 said:
The aim of the partnership with Novogen is to bring a new class of anticancer drugs to the point of human trials....
From Graham Kelly's CV:
Graham Kelly has overseen the design and implementation of thirty-three Phase I and II clinical trials, and a multinational Phase III trial in conjunction with the US FDA.
The Phase 3 trial was the Overture - Phenodoxial trial that was cut short after Graham Kelly had already resigned in 2007.
Professor Gunning and the Kids Cancer Project had been developing and funding the ATM's for years - Graham Kelly had never taken a drug THROUGH a phase 3 trial - successfully or unsuccessfully. My understanding is that he sold most of these programs off or partnered them out to others or they stopped.
Genscreen were clearly of the impression Graham Kelly's involvement would be only up to the point of human trials which sounds completely consistent with the way he had operated for all those years with cosmetic face creams, menopause treatments and the like - in fact he seems to have tried out all kinds of products..
I think what we're seeing in the delays is that at least some of the programs should have been moved on by now and Graham Kelly did take CanTx to the Bio this year and was over there for some time and it looks like he didn't succeed in gaining any new partners or whatever over there so where to from there when the company was cashed up and looking good and you still couldn't attract new partners in the US...Graham Kelly had literally come to the end of what he could contribute..which is also reflected in the people he'd been appointing to the board to try and build bridges..
Structure
Novogen has structured its R&D activities and IP portfolio into 4 entities as shown below.
The purpose of this structure is to allow discrete commercialization opportunities to be pursued with specific partners without risk of cross-over issues.
CanTx Inc is limited to SBP drugs delivered directly into the peritoneal cavity and the pleural cavity. CanTx is a joint venture company between Novogen and Yale University.
NewCo 1 contains all other SBP IP related to the field of oncology. The current two lead candidates are TRXE-009 (Trilexium) and TRXE-0025.
NewCo 2 contains the SBP IP related to non-oncology (degenerative diseases) fields (Project Jacob Hope). Current studies are determining lead candidate compounds in such fields as muscular dystrophy, Alzheimer’s Diseases, and San Filippo Syndrome.
NewCo 3 contains all the ATM platform IP. One lead drug, Anisina, is identified.
http://www.novogen.com/history.html
